Pearl from the Bruce Patterson interview on Dr. Yo: the high death rate in S/C trials means we have greater chance at significance. Any deaths are terrible but primary end point being mortality at 28 days means that if no deaths in study then no chance at statistical significance....So you have to ask yourself, what is the most likely scenario? Deaths in placebo and treatment arms are equivalent or deaths in placebo are significantly higher than leronlimab arm?